VIR

5.60

6.04% -0.36

Vorhandelsmarkt: 5.54 -0.06 -1.07%

Vir Biotechnology Inc (VIR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt VIR? Forum Prognose

Schlusskurs vom Vortag:

$5.96

Offen:

$5.91

24-Stunden-Volumen:

1.43M

Relative Volume:

1.02

Marktkapitalisierung:

$777.93M

Einnahmen:

$62.04M

Nettoeinkommen (Verlust:

$-533.34M

KGV:

-1.4286

EPS:

-3.92

Netto-Cashflow:

$-473.07M

1W Leistung:

-9.53%

1M Leistung:

-2.27%

6M Leistung:

-9.09%

1J Leistung:

-39.52%

1-Tages-Spanne:

$5.50

$5.97

1-Wochen-Bereich:

$5.50

$6.555

52-Wochen-Spanne:

$4.155

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Firmenname

Vir Biotechnology Inc

Sektor

Healthcare (1136)

Branche

Biotechnology (633)

Telefon

415-906-4324

Adresse

1800 OWENS STREET, SAN FRANCISCO, CA

Mitarbeiter

408

Twitter

@Vir_Biotech

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

VIR's Discussions on Twitter

Vergleichen Sie VIR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
VIR Vir Biotechnology Inc	5.60	827.94M	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	426.00	109.11B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	642.25	68.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	434.07	60.25B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	826.28	50.39B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	186.23	40.44B	447.02M	-1.18B	-868.57M	-6.1812

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-03	Eingeleitet	Evercore ISI	Outperform
2025-08-27	Hochstufung	BofA Securities	Neutral → Buy
2024-01-29	Herabstufung	JP Morgan	Overweight → Neutral
2023-09-08	Herabstufung	BofA Securities	Buy → Neutral
2023-03-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-02-21	Hochstufung	Goldman	Neutral → Buy
2023-01-27	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-09-14	Eingeleitet	SVB Leerink	Outperform
2022-09-09	Eingeleitet	Morgan Stanley	Underweight
2022-03-03	Hochstufung	Robert W. Baird	Underperform → Neutral
2021-12-21	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-10-25	Hochstufung	JP Morgan	Underweight → Neutral
2021-09-22	Herabstufung	Goldman	Buy → Neutral
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-01-27	Herabstufung	JP Morgan	Neutral → Underweight
2021-01-20	Bestätigt	H.C. Wainwright	Buy
2020-10-05	Eingeleitet	BofA Securities	Buy
2020-09-14	Hochstufung	Goldman	Neutral → Buy
2020-09-11	Hochstufung	JP Morgan	Underweight → Neutral
2020-08-20	Eingeleitet	Needham	Buy
2020-03-19	Herabstufung	JP Morgan	Neutral → Underweight
2020-03-13	Herabstufung	Goldman	Buy → Neutral
2020-02-27	Herabstufung	Robert W. Baird	Neutral → Underperform
2020-02-04	Herabstufung	JP Morgan	Overweight → Neutral
2019-11-14	Eingeleitet	Robert W. Baird	Neutral
2019-11-05	Eingeleitet	Barclays	Overweight
2019-11-05	Eingeleitet	Cowen	Outperform
2019-11-05	Eingeleitet	Goldman	Buy
2019-11-05	Eingeleitet	JP Morgan	Overweight

Alle ansehen

Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten

05:51 AM

Vir Biotechnology concludes Eclipse 1 Phase III trial enrolment for CHD - Yahoo

05:51 AM

05:17 AM

How Vir Biotechnology Inc. stock reacts to job market dataTrade Exit Summary & High Accuracy Trade Alerts - newser.com

05:17 AM

04:02 AM

What to do if you’re stuck in Vir Biotechnology Inc.Trade Risk Report & Target Return Focused Stock Picks - newser.com

04:02 AM

01:49 AM

How Vir Biotechnology Inc. stock reacts to oil pricesJuly 2025 Big Picture & AI Based Buy/Sell Signal Reports - newser.com

01:49 AM

Nov 03, 2025

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta - BioSpace

Nov 03, 2025

Top chart patterns to watch in Vir Biotechnology Inc.Rate Cut & High Return Trade Opportunity Guides - newser.com

Nov 03, 2025

Why Vir Biotechnology Inc. stock is favored by top institutionsPortfolio Profit Report & Verified Swing Trading Watchlists - newser.com

Nov 03, 2025

Is it too late to sell Vir Biotechnology Inc.Gold Moves & Detailed Earnings Play Alerts - newser.com

Nov 03, 2025

Vir Biotechnology (VIR) Completes Enrollment for ECLIPSE 1 Trial - GuruFocus

Nov 03, 2025

Vir Biotechnology (NASDAQ: VIR) announces ECLIPSE 1 full enrollment; topline data Q1 2027 - Stock Titan

Nov 03, 2025

Tools to monitor Vir Biotechnology Inc. recovery probabilityJuly 2025 Analyst Calls & Expert Approved Momentum Ideas - newser.com

Nov 03, 2025

Vir Biotechnology Inc. stock trendline breakdownPortfolio Return Summary & Verified Momentum Stock Ideas - newser.com

Nov 03, 2025

Why Vir Biotechnology Inc. stock remains on watchlistsWeekly Volume Report & Weekly Market Pulse Updates - newser.com

Nov 03, 2025

How to manage a losing position in Vir Biotechnology Inc.2025 Analyst Calls & AI Driven Stock Reports - newser.com

Nov 03, 2025

Can technical indicators confirm Vir Biotechnology Inc.’s reversalIPO Watch & Expert Curated Trade Ideas - newser.com

Nov 03, 2025

Pattern recognition hints at Vir Biotechnology Inc. upside2025 Market Trends & Weekly Consistent Profit Watchlists - newser.com

Nov 03, 2025

Published on: 2025-11-03 02:05:03 - newser.com

Nov 03, 2025

Best data tools to analyze Vir Biotechnology Inc. stockForecast Cut & Real-Time Volume Spike Alerts - newser.com

Nov 03, 2025

How to escape a deep drawdown in Vir Biotechnology Inc.Insider Buying & AI Based Buy/Sell Signal Reports - newser.com

Nov 03, 2025

Nov 02, 2025

Will Vir Biotechnology Inc. stock deliver consistent dividends2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com

Nov 02, 2025

Is now a turning point for Vir Biotechnology Inc.July 2025 Fed Impact & Community Consensus Picks - newser.com

Nov 02, 2025

Is Vir Biotechnology Inc. forming a reversal patternJuly 2025 Technicals & Real-Time Volume Triggers - newser.com

Nov 02, 2025